PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16120440-2 2005 To study the function of p53 in a keratinocyte background, a tetracycline-controlled p53 transgene was introduced into a human SCC cell line (SCC15), lacking endogenous p53. Tetracycline 61-73 tumor protein p53 Homo sapiens 85-88 16624812-3 2006 To further understand how excess HDM2 regulates p53-mediated functions, we generated H1299 cell clones that constitutively express both ectopic HDM2 and tetracycline-regulated inducible p53. Tetracycline 153-165 tumor protein p53 Homo sapiens 48-51 16624812-3 2006 To further understand how excess HDM2 regulates p53-mediated functions, we generated H1299 cell clones that constitutively express both ectopic HDM2 and tetracycline-regulated inducible p53. Tetracycline 153-165 tumor protein p53 Homo sapiens 186-189 16966095-2 2006 Using a model cell line in which p53 expression is regulated exogenously in a tetracycline-off system (TR9-7 cells) , our laboratory has shown that arsenite disrupts mitosis and that p53-deficient cells [p53(-)], in contrast to p53-expressing cells [p53(+)], display greater sensitivity to arsenite-induced mitotic arrest and apoptosis. Tetracycline 78-90 tumor protein p53 Homo sapiens 33-36 16120440-2 2005 To study the function of p53 in a keratinocyte background, a tetracycline-controlled p53 transgene was introduced into a human SCC cell line (SCC15), lacking endogenous p53. Tetracycline 61-73 tumor protein p53 Homo sapiens 85-88 16120440-3 2005 Conditional expression of wild-type p53 protein upon withdrawal of tetracycline was accompanied with increased expression of p21(WAF1/Cip1) resulting in reduced cell proliferation. Tetracycline 67-79 tumor protein p53 Homo sapiens 36-39 15319038-4 2004 Coinfection of Ad vectors containing the siRNA expression system under the control of the Dox-inducible H1 promoter and Ad vectors expressing a tetracycline repressor inhibited the expression levels of p53 and c-Myc in a dose-dependent manner with both Dox and viral dose. Tetracycline 144-156 tumor protein p53 Homo sapiens 202-205 15998635-3 2005 MIRA-1 induced mutant p53-dependent cell death in different human tumor cells carrying tetracycline-regulated mutant p53. Tetracycline 87-99 tumor protein p53 Homo sapiens 22-25 15998635-3 2005 MIRA-1 induced mutant p53-dependent cell death in different human tumor cells carrying tetracycline-regulated mutant p53. Tetracycline 87-99 tumor protein p53 Homo sapiens 117-120 15087457-8 2004 In addition, the dependence on p53 was confirmed using a second cell type operating a tetracycline-inducible system. Tetracycline 86-98 tumor protein p53 Homo sapiens 31-34 15111320-6 2004 The Ishikawa cell line, with stable or tetracycline-regulated expression of mutant beta-catenin, showed an increase in expression levels of cyclin D1, p14ARF, p53, and p21WAF1 but not PML, and activation of beta-catenin-TCF4-mediated transcription determined with TOP/FOP constructs. Tetracycline 39-51 tumor protein p53 Homo sapiens 159-162 14990579-7 2004 Tetracycline-regulated IFI16 also induced apoptosis when coexpressed with p53 in p53-deficient EJ cells subjected to IR, suggesting that IFI16 is involved in p53-mediated transmission of apoptosis signaling. Tetracycline 0-12 tumor protein p53 Homo sapiens 74-77 14990579-7 2004 Tetracycline-regulated IFI16 also induced apoptosis when coexpressed with p53 in p53-deficient EJ cells subjected to IR, suggesting that IFI16 is involved in p53-mediated transmission of apoptosis signaling. Tetracycline 0-12 tumor protein p53 Homo sapiens 81-84 14990579-7 2004 Tetracycline-regulated IFI16 also induced apoptosis when coexpressed with p53 in p53-deficient EJ cells subjected to IR, suggesting that IFI16 is involved in p53-mediated transmission of apoptosis signaling. Tetracycline 0-12 tumor protein p53 Homo sapiens 81-84 12439598-8 2002 Treatment of cells with PD98059 or UO126 after cisplatin incubation or inhibition of signaling through ERK by tetracycline-regulated expression of dominant-inhibitory ERK enhanced resistance to cisplatin in p53-negative osteosarcoma cells and reduced cisplatin-induced apoptosis. Tetracycline 110-122 tumor protein p53 Homo sapiens 207-210 12702563-2 2003 We have used microPET and fluorescence imaging to detect interactions between p53 tumor suppressor and large T antigen (TAg) of SV40 virus in a tetracycline-inducible two-hybrid system. Tetracycline 144-156 tumor protein p53 Homo sapiens 78-81 12624953-3 2003 To study the effect of dominant-negative inhibitor GSE22 on the p53 activity, cultures coexpressing GSE22 and tetracycline-suppressible p53 were derived from p53-negative cell lines. Tetracycline 110-122 tumor protein p53 Homo sapiens 136-139 12624953-3 2003 To study the effect of dominant-negative inhibitor GSE22 on the p53 activity, cultures coexpressing GSE22 and tetracycline-suppressible p53 were derived from p53-negative cell lines. Tetracycline 110-122 tumor protein p53 Homo sapiens 136-139 12374798-2 2002 We investigated possible alterations of MUC2 gene expression by p53 and p21(Sdi1/Waf1/Cip1) in a human colon cancer cell line, DLD-1, establishing subclones in which a tetracycline-regulatable promoter controls exogenous p53 and p21 expression. Tetracycline 168-180 tumor protein p53 Homo sapiens 221-224 12096336-6 2002 Using tetracycline-regulated retroviral vectors for conditional expression of p53 mutants, we found that transcription of the dUTPase gene is increased within 24 h after tetracycline withdrawal, and the cells acquire higher resistance to 5-FU. Tetracycline 6-18 tumor protein p53 Homo sapiens 78-81 12234998-2 2002 We have measured the formation and nucleotide excision repair of covalent DNA adducts formed by the DNA-reactive metabolite of this compound in human fibroblasts, in which expression of the p53 tumor suppressor gene could be controlled by a tetracycline-inducible promoter. Tetracycline 241-253 tumor protein p53 Homo sapiens 190-193 12096336-6 2002 Using tetracycline-regulated retroviral vectors for conditional expression of p53 mutants, we found that transcription of the dUTPase gene is increased within 24 h after tetracycline withdrawal, and the cells acquire higher resistance to 5-FU. Tetracycline 170-182 tumor protein p53 Homo sapiens 78-81 11373271-4 2001 We established tetracycline-regulated, stable hRAD50 expression systems in SaOS-2 cells, which retain mutated p53, and in HeLa cells. Tetracycline 15-27 tumor protein p53 Homo sapiens 110-113 11892838-2 2001 We therefore used a p53-null human NSCLC cell line in which we reintroduced the wild-type p53 gene under control of a tetracycline-dependent promoter. Tetracycline 118-130 tumor protein p53 Homo sapiens 20-23 11892838-2 2001 We therefore used a p53-null human NSCLC cell line in which we reintroduced the wild-type p53 gene under control of a tetracycline-dependent promoter. Tetracycline 118-130 tumor protein p53 Homo sapiens 90-93 11489880-2 2001 In the present study, we investigated this cell death pathway by stably transfecting the p53-null H358 cell line with a tetracycline-dependent wild type p53-expressing vector. Tetracycline 120-132 tumor protein p53 Homo sapiens 89-92 11489880-2 2001 In the present study, we investigated this cell death pathway by stably transfecting the p53-null H358 cell line with a tetracycline-dependent wild type p53-expressing vector. Tetracycline 120-132 tumor protein p53 Homo sapiens 153-156 11593387-3 2001 Here, we report that p63, like p53 and p73, induces replicative senescence when expressed in a tetracycline-regulated manner in EJ cells lacking a functional p53. Tetracycline 95-107 tumor protein p53 Homo sapiens 31-34 11536301-4 2001 METHODS: A conditional eukaryotic expression vector (under tetracycline regulation) expressing antisense p53 cDNA was constructed and either directly transfected into LNCaP cells or tranduced into these cells using recombinant retroviruses containing the vector. Tetracycline 59-71 tumor protein p53 Homo sapiens 105-108 11375983-3 2001 When ectopic wild-type p53 expression was induced to a physiologically relevant level in "tet-off" cultured cells in which p53 expression was tightly regulated by tetracycline, it was found that POLD1 steady-state mRNA was repressed by about 65%. Tetracycline 163-175 tumor protein p53 Homo sapiens 23-26 11375983-3 2001 When ectopic wild-type p53 expression was induced to a physiologically relevant level in "tet-off" cultured cells in which p53 expression was tightly regulated by tetracycline, it was found that POLD1 steady-state mRNA was repressed by about 65%. Tetracycline 163-175 tumor protein p53 Homo sapiens 123-126 11434920-2 2001 We established osteosarcoma cell lines in which a tetracycline-regulatable promoter controls the induction of RB, p53 and p21. Tetracycline 50-62 tumor protein p53 Homo sapiens 114-117 11158294-5 2001 We found that induction of p53 either by diverse stress signals or ectopically using a tetracycline-regulated promoter causes a marked reduction in CHK1 protein levels. Tetracycline 87-99 tumor protein p53 Homo sapiens 27-30 11350911-2 2001 A p53-null, MGMT-proficient lung tumor cell line (H1299) was engineered to express wt p53 in a tetracycline-regulated system. Tetracycline 95-107 tumor protein p53 Homo sapiens 86-89 11350911-3 2001 High levels of p53 induction achieved by tetracycline withdrawal were accompanied by G(1) cell cycle arrest without significant apoptosis in this cell line. Tetracycline 41-53 tumor protein p53 Homo sapiens 15-18 10531402-2 1999 When cells were grown in media containing normal concentrations (10%) of serum, induction of p53 by tetracycline withdrawal resulted in an 8-fold decrease in sensitivity to CP. Tetracycline 100-112 tumor protein p53 Homo sapiens 93-96 11108661-3 2000 When a tetracycline-regulatable dominant-negative c-jun (TAM67, having a truncated transactivation domain) was expressed in tumorigenic human keratinocytes, AP-1- and NFkappaB- but not p53-dependent reporter activity was inhibited by 40-60%. Tetracycline 7-19 tumor protein p53 Homo sapiens 185-188 10588737-2 1999 A modified tetracycline-inducible system was established to search for transcripts that were activated soon after p53 induction. Tetracycline 11-23 tumor protein p53 Homo sapiens 114-117 11027272-5 2000 Likewise, expression of a tetracycline-regulated wild-type p53 cDNA in p53-null fibroblasts caused a reduction in 53BP2 protein levels. Tetracycline 26-38 tumor protein p53 Homo sapiens 59-62 11027272-5 2000 Likewise, expression of a tetracycline-regulated wild-type p53 cDNA in p53-null fibroblasts caused a reduction in 53BP2 protein levels. Tetracycline 26-38 tumor protein p53 Homo sapiens 71-74 11027272-6 2000 However, 53BP2 levels were not reduced if the tetracycline-regulated p53 cDNA was expressed after UV damage in these cells. Tetracycline 46-58 tumor protein p53 Homo sapiens 69-72 10467417-5 1999 Using a series of point and deletion mutants of p53 under the control of tetracycline-regulated promoter we show that certain mutants, like the wild type, protect cells at low levels but lead to apoptosis when overexpressed. Tetracycline 73-85 tumor protein p53 Homo sapiens 48-51 9891091-7 1999 Treatment of RKO cells with a tetracycline derivative, doxycycline, resulted in 15-fold-induced expression of TS protein and nearly complete suppression of p53 protein expression. Tetracycline 30-42 tumor protein p53 Homo sapiens 156-159 9766676-7 1998 Moreover, analysis of a tetracycline-regulated p53-inducible system in null-p53 cell lines showed that RTP/rit42 mRNA expression increased concomitantly with p53 expression and followed a similar time course. Tetracycline 24-36 tumor protein p53 Homo sapiens 47-50 9927213-4 1999 This hybrid protein binds to p53 and can interact with a synthetic promoter containing tetracycline-operator sequences. Tetracycline 87-99 tumor protein p53 Homo sapiens 29-32 10023442-9 1998 We also provided wild-type p53 and p53 delta 326 with tetracycline-regulated promoters and stably introduced these constructs into Saos2 and SKBR3 cells. Tetracycline 54-66 tumor protein p53 Homo sapiens 35-38 9772303-5 1998 Tetracycline-inducible antisense expression of HPV18 E6 in human cervical carcinoma HeLa cells resulted in increased level of p53 but did not affect expression of MN/CA IX protein. Tetracycline 0-12 tumor protein p53 Homo sapiens 126-129 9766676-7 1998 Moreover, analysis of a tetracycline-regulated p53-inducible system in null-p53 cell lines showed that RTP/rit42 mRNA expression increased concomitantly with p53 expression and followed a similar time course. Tetracycline 24-36 tumor protein p53 Homo sapiens 76-79 9766676-7 1998 Moreover, analysis of a tetracycline-regulated p53-inducible system in null-p53 cell lines showed that RTP/rit42 mRNA expression increased concomitantly with p53 expression and followed a similar time course. Tetracycline 24-36 tumor protein p53 Homo sapiens 76-79 11245004-0 1998 [A study on the tumor suppressing effect of a specific point mutant p53 minigene in the expression regulated model with a tetracycline-transactivative response promoter]. Tetracycline 122-134 tumor protein p53 Homo sapiens 68-71 11245004-1 1998 OBJECTIVE: To establish a tetracycline-regulated expression model and to determine and verify whether a specific point mutant type p53 minigene, containing an Arg-->Leu substitution at amino acid 172, possesses a suppressing effect on human lung cancer. Tetracycline 26-38 tumor protein p53 Homo sapiens 131-134 11245004-3 1998 Then the specific p53 minigene was sub-cloned into a tetracycline-transactivative controlled expression vector pBPSTR1 by gene recombination methods. Tetracycline 53-65 tumor protein p53 Homo sapiens 18-21 11245004-6 1998 The tetracycline transactivative p53 minigene-regulated transgene model was successfully established. Tetracycline 4-16 tumor protein p53 Homo sapiens 33-36 9492043-3 1998 The p53-induced regulation of IGF-IR levels was studied in a tetracycline-regulated expression system. Tetracycline 61-73 tumor protein p53 Homo sapiens 4-7 9661919-5 1998 We found that these cells are positive for Ki-67 even when they are arrested in G1/S or G2/M by using synchronizing inhibitors, by inducing p21(Waf1/Cip1) in a tetracycline-regulated expression system or by inducing wild type p53 and p21 after inflicting DNA damage. Tetracycline 160-172 tumor protein p53 Homo sapiens 226-229 9575175-6 1998 Employing a stable cell line derived from p53-deficient human fibroblast that contains tetracycline-regulated transactivator and operator plasmids to control the expression of wild-type p53 (TR9-7 cells), we then show that the induction of p21(WAF1/Cip1), which occurs in response to the inhibition of PP5 expression, requires the p53 protein. Tetracycline 87-99 tumor protein p53 Homo sapiens 186-189 9575175-6 1998 Employing a stable cell line derived from p53-deficient human fibroblast that contains tetracycline-regulated transactivator and operator plasmids to control the expression of wild-type p53 (TR9-7 cells), we then show that the induction of p21(WAF1/Cip1), which occurs in response to the inhibition of PP5 expression, requires the p53 protein. Tetracycline 87-99 tumor protein p53 Homo sapiens 186-189 7667317-2 1995 To study the effects of p53 without the complication of DNA damage, we used tetracycline to regulate its expression in MDAH041 human fibroblasts that lack endogenous p53. Tetracycline 76-88 tumor protein p53 Homo sapiens 24-27 9467956-3 1998 Here, we show, using a tetracycline-regulated system, that expression of wild-type p21 in p53-deficient DLD1 human colon cancer cells inhibits DNA synthesis and causes G1 and G2 cell cycle arrest. Tetracycline 23-35 tumor protein p53 Homo sapiens 90-93 9346961-9 1997 The specificity of the effect of wild-type p53 on nucleotide excision repair was demonstrated in a p53 homozygous mutant cell line containing a tetracycline-regulated wild-type p53 gene. Tetracycline 144-156 tumor protein p53 Homo sapiens 43-46 9346961-9 1997 The specificity of the effect of wild-type p53 on nucleotide excision repair was demonstrated in a p53 homozygous mutant cell line containing a tetracycline-regulated wild-type p53 gene. Tetracycline 144-156 tumor protein p53 Homo sapiens 99-102 9346961-9 1997 The specificity of the effect of wild-type p53 on nucleotide excision repair was demonstrated in a p53 homozygous mutant cell line containing a tetracycline-regulated wild-type p53 gene. Tetracycline 144-156 tumor protein p53 Homo sapiens 99-102 9346961-10 1997 Wild-type p53 expression and activity were suppressed in the presence of tetracycline, whereas withdrawal of tetracycline resulted in the induction of p53 expression, cell cycle checkpoint activation, and DNA damage-induced apoptosis. Tetracycline 73-85 tumor protein p53 Homo sapiens 10-13 9346961-10 1997 Wild-type p53 expression and activity were suppressed in the presence of tetracycline, whereas withdrawal of tetracycline resulted in the induction of p53 expression, cell cycle checkpoint activation, and DNA damage-induced apoptosis. Tetracycline 109-121 tumor protein p53 Homo sapiens 151-154 9150394-0 1997 Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Tetracycline 74-86 tumor protein p53 Homo sapiens 107-110 8809405-2 1996 To assess the biological significance of p53 inactivation in the development of SCLC, tetracycline (Tc)-inducible p53 expression plasmids were introduced into a SCLC cell line, N417, in which the p53 gene as well as the RB gene was inactivated. Tetracycline 86-98 tumor protein p53 Homo sapiens 114-117 8809405-2 1996 To assess the biological significance of p53 inactivation in the development of SCLC, tetracycline (Tc)-inducible p53 expression plasmids were introduced into a SCLC cell line, N417, in which the p53 gene as well as the RB gene was inactivated. Tetracycline 86-98 tumor protein p53 Homo sapiens 114-117 8809405-2 1996 To assess the biological significance of p53 inactivation in the development of SCLC, tetracycline (Tc)-inducible p53 expression plasmids were introduced into a SCLC cell line, N417, in which the p53 gene as well as the RB gene was inactivated. Tetracycline 100-102 tumor protein p53 Homo sapiens 114-117 8809405-2 1996 To assess the biological significance of p53 inactivation in the development of SCLC, tetracycline (Tc)-inducible p53 expression plasmids were introduced into a SCLC cell line, N417, in which the p53 gene as well as the RB gene was inactivated. Tetracycline 100-102 tumor protein p53 Homo sapiens 114-117 8809405-5 1996 Thus, wild-type p53-inducible clones were further established by transfection in the presence (repressed) of Tc. Tetracycline 109-111 tumor protein p53 Homo sapiens 16-19 7667317-6 1995 MDAH041 cells arrested by tetracycline-regulated p53 for as long as 20 days resumed growth when the p53 level was lowered, in striking contrast to the irreversible arrest mediated by DNA damage. Tetracycline 26-38 tumor protein p53 Homo sapiens 49-52 7667317-6 1995 MDAH041 cells arrested by tetracycline-regulated p53 for as long as 20 days resumed growth when the p53 level was lowered, in striking contrast to the irreversible arrest mediated by DNA damage. Tetracycline 26-38 tumor protein p53 Homo sapiens 100-103 7531056-2 1994 Here, we tested the role of p53 in the angiogenic process by introducing a tetracycline-regulated wild type p53 gene into null glioblastoma cells. Tetracycline 75-87 tumor protein p53 Homo sapiens 28-31 7938006-2 1994 Using a tetracycline-regulated p53 expression system and cDNA library subtraction procedure, we identified several p53-induced gene transcripts in human Saos-2 osteosarcoma cells that are novel on the basis of their size, regulation, and low abundance. Tetracycline 8-20 tumor protein p53 Homo sapiens 31-34 7938006-2 1994 Using a tetracycline-regulated p53 expression system and cDNA library subtraction procedure, we identified several p53-induced gene transcripts in human Saos-2 osteosarcoma cells that are novel on the basis of their size, regulation, and low abundance. Tetracycline 8-20 tumor protein p53 Homo sapiens 115-118 7531056-2 1994 Here, we tested the role of p53 in the angiogenic process by introducing a tetracycline-regulated wild type p53 gene into null glioblastoma cells. Tetracycline 75-87 tumor protein p53 Homo sapiens 108-111 32942535-5 2020 Using H1299 cells, which are null for TP53, we generated cell lines expressing either a tetracycline inducible wild-type (WT) TP53 gene, or a representative mutated TP53 gene from six exemplary "hotspot" mutations in the DNA binding domain (R273H, R248Q, R282W, R175H, G245S, and R249S). Tetracycline 88-100 tumor protein p53 Homo sapiens 126-130 32942535-5 2020 Using H1299 cells, which are null for TP53, we generated cell lines expressing either a tetracycline inducible wild-type (WT) TP53 gene, or a representative mutated TP53 gene from six exemplary "hotspot" mutations in the DNA binding domain (R273H, R248Q, R282W, R175H, G245S, and R249S). Tetracycline 88-100 tumor protein p53 Homo sapiens 126-130 25444916-8 2015 Conditional knockdown of p53 by tetracycline inducible expression system significantly abrogated curcumin-induced miR-192-5p/215 upregulation in the p53 wild-type H460, A427 and A549 cells. Tetracycline 32-44 tumor protein p53 Homo sapiens 25-28 27698449-7 2016 A tetracycline-inducible lentiviral expression system containing shRNA to p53 was used to knockout p53. Tetracycline 2-14 tumor protein p53 Homo sapiens 74-77 27698449-7 2016 A tetracycline-inducible lentiviral expression system containing shRNA to p53 was used to knockout p53. Tetracycline 2-14 tumor protein p53 Homo sapiens 99-102 25444916-8 2015 Conditional knockdown of p53 by tetracycline inducible expression system significantly abrogated curcumin-induced miR-192-5p/215 upregulation in the p53 wild-type H460, A427 and A549 cells. Tetracycline 32-44 tumor protein p53 Homo sapiens 149-152 19602589-5 2009 To investigate the role of GPR87 in the p53 pathway, we generated multiple RKO and MCF7 cell lines in that GPR87 can be inducibly overexpressed or knocked down by a tetracycline-inducible system. Tetracycline 165-177 tumor protein p53 Homo sapiens 40-43 19639960-4 2009 We used a clone of H358, stably transfected with a tetracycline-inducible wild-type p53-expressing vector. Tetracycline 51-63 tumor protein p53 Homo sapiens 84-87 18801387-5 2009 The tetracycline inducible promoter, cloned in opposite orientation to the ROSA26 locus and separated from the rtTA element by a 5 kb human p53 intron, drives Cre recombinase expression. Tetracycline 4-16 tumor protein p53 Homo sapiens 140-143 18267949-6 2008 We have used a (32)P-postlabelling method to monitor the removal of GpG- and ApG-intrastrand cross links from two human cell models (the 041TR system, in which p53 is regulated by a tetracycline-inducible promoter, together with WI38 fibroblasts and the SV40-transformed derivative VA13) that each differ in p53 status. Tetracycline 182-194 tumor protein p53 Homo sapiens 160-163 17363597-7 2007 Furthermore, using the H1299-HW24 cells expressing wild-type p53 under a tetracycline-regulated promoter, the p53-MDM2 oscillation was observed only when p53 levels were in a specific range, and DNA damage was found to be necessary for triggering the p53-MDM2 oscillation. Tetracycline 73-85 tumor protein p53 Homo sapiens 61-64 18003626-5 2008 Two cell models were selected: 041 TR fibroblasts in which the expression of p53 is regulated by a tetracycline-inducible promoter, and WI38 primary lung fibroblasts together with their isogenic derivative VA13, in which p53 is abrogated post-translationally by SV40 transformation. Tetracycline 99-111 tumor protein p53 Homo sapiens 77-80 21603516-5 2007 EXPERIMENTAL DESIGN: The p53-null human erythroleukemia cell line, K-562, was stably transfected with a tetracycline-repressible p53 expression construct (p53/pUHD10-3). Tetracycline 104-116 tumor protein p53 Homo sapiens 25-28 21603516-5 2007 EXPERIMENTAL DESIGN: The p53-null human erythroleukemia cell line, K-562, was stably transfected with a tetracycline-repressible p53 expression construct (p53/pUHD10-3). Tetracycline 104-116 tumor protein p53 Homo sapiens 129-132 21603516-5 2007 EXPERIMENTAL DESIGN: The p53-null human erythroleukemia cell line, K-562, was stably transfected with a tetracycline-repressible p53 expression construct (p53/pUHD10-3). Tetracycline 104-116 tumor protein p53 Homo sapiens 129-132 21603516-6 2007 p53 protein in these cells is expressed in the absence of tetracycline but down-regulated upon tetracycline treatment. Tetracycline 58-70 tumor protein p53 Homo sapiens 0-3 21603516-6 2007 p53 protein in these cells is expressed in the absence of tetracycline but down-regulated upon tetracycline treatment. Tetracycline 95-107 tumor protein p53 Homo sapiens 0-3 17363597-7 2007 Furthermore, using the H1299-HW24 cells expressing wild-type p53 under a tetracycline-regulated promoter, the p53-MDM2 oscillation was observed only when p53 levels were in a specific range, and DNA damage was found to be necessary for triggering the p53-MDM2 oscillation. Tetracycline 73-85 tumor protein p53 Homo sapiens 110-113 17363597-7 2007 Furthermore, using the H1299-HW24 cells expressing wild-type p53 under a tetracycline-regulated promoter, the p53-MDM2 oscillation was observed only when p53 levels were in a specific range, and DNA damage was found to be necessary for triggering the p53-MDM2 oscillation. Tetracycline 73-85 tumor protein p53 Homo sapiens 110-113 17363597-7 2007 Furthermore, using the H1299-HW24 cells expressing wild-type p53 under a tetracycline-regulated promoter, the p53-MDM2 oscillation was observed only when p53 levels were in a specific range, and DNA damage was found to be necessary for triggering the p53-MDM2 oscillation. Tetracycline 73-85 tumor protein p53 Homo sapiens 110-113 17283151-8 2007 In the stable H1299 cell line with tetracycline-inducible p53 expression, induced p53 enhanced growth inhibition and apoptosis by gefitinib through the up-regulation of Fas and restoration of caspase activation. Tetracycline 35-47 tumor protein p53 Homo sapiens 58-61 17283151-8 2007 In the stable H1299 cell line with tetracycline-inducible p53 expression, induced p53 enhanced growth inhibition and apoptosis by gefitinib through the up-regulation of Fas and restoration of caspase activation. Tetracycline 35-47 tumor protein p53 Homo sapiens 82-85 17210690-2 2007 To identify novel regulators of p53, we have used a phenotype-based selection in which a total cDNA library in a retroviral vector has been introduced into TR9-7ER cells, which arrest when p53 is expressed from a tetracycline-regulated promoter. Tetracycline 213-225 tumor protein p53 Homo sapiens 189-192